Lixte Biotechnology Holdings Stock Today
LIXT Stock | USD 3.50 0.20 6.06% |
Performance12 of 100
| Odds Of DistressOver 67
|
Lixte Biotechnology is selling for under 3.50 as of the 17th of April 2024; that is 6.06 percent increase since the beginning of the trading day. The stock's last reported lowest price was 3.35. Lixte Biotechnology has more than 67 % chance of experiencing financial distress in the next few years of operation. However, it had a very good returns during the last 90 days. Equity ratings for Lixte Biotechnology Holdings are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 18th of March 2024 and ending today, the 17th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 21st of September 2007 | Category Healthcare | Classification Health Care |
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company was founded in 2005 and is based in Pasadena, California. The company has 2.25 M outstanding shares of which 16.72 K shares are now shorted by private and institutional investors with about 0.01 trading days to cover. More on Lixte Biotechnology Holdings
Moving together with Lixte Stock
0.69 | MRK | Merck Company Report 25th of April 2024 | PairCorr |
Moving against Lixte Stock
0.81 | BIIB | Biogen Inc Earnings Call This Week | PairCorr |
0.7 | VRTX | Vertex Pharmaceuticals Financial Report 6th of May 2024 | PairCorr |
0.64 | JNJ | Johnson Johnson Financial Report 18th of July 2024 | PairCorr |
0.64 | AMGN | Amgen Inc Financial Report 25th of April 2024 | PairCorr |
Lixte Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Lixte Biotechnology's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Lixte Biotechnology or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
CEO, CFO, Director | John Kovach | |||||||||||||||||||||||||||||||||||||||||||||
Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
Financial Strength Based on the key measurements obtained from Lixte Biotechnology's financial statements, Lixte Biotechnology Holdings may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. Financial strength of Lixte Biotechnology is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
|
Lixte Biotechnology Holdings (LIXT) is traded on NASDAQ Exchange in USA. It is located in 680 East Colorado Boulevard, Pasadena, CA, United States, 91101 and employs 3 people. Lixte Biotechnology is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 7.87 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Lixte Biotechnology's market, we take the total number of its shares issued and multiply it by Lixte Biotechnology's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Lixte Biotechnology conducts business under Biotechnology sector and is part of Health Care industry. The entity has 2.25 M outstanding shares of which 16.72 K shares are now shorted by private and institutional investors with about 0.01 trading days to cover.
Lixte Biotechnology Holdings currently holds about 7.74 M in cash with (4.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.47.
Check Lixte Biotechnology Probability Of Bankruptcy
Ownership AllocationLixte Biotechnology Holdings holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months.
Check Lixte Ownership Details
Lixte Stock Price Odds Analysis
Attributed to a normal probability distribution, the odds of Lixte Biotechnology jumping above the current price in 90 days from now is roughly 2.97%. The Lixte Biotechnology Holdings probability density function shows the probability of Lixte Biotechnology stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 2.5236. This indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Lixte Biotechnology will likely underperform. Moreover, lixte Biotechnology Holdings has an alpha of 1.0634, implying that it can generate a 1.06 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Lixte Biotechnology to move above the current price in 90 days from now is roughly 2.97 (This Lixte Biotechnology Holdings probability density function shows the probability of Lixte Stock to fall within a particular range of prices over 90 days) .
Lixte Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Lixte Biotechnology that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Lixte Biotechnology's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Lixte Biotechnology's value.Instituion | Recorded On | Shares | |
Hightower Advisors, Llc | 2023-12-31 | 99.4 K | |
Morgan Stanley - Brokerage Accounts | 2023-12-31 | 7.1 K | |
Fny Investment Advisers, Llc | 2023-12-31 | 5.5 K | |
Tower Research Capital Llc | 2023-12-31 | 2.2 K | |
Wells Fargo & Co | 2023-12-31 | 9.0 | |
Ubs Group Ag | 2023-12-31 | 3.0 | |
Ethos Financial Group Llc | 2023-12-31 | 0.0 | |
Geode Capital Management, Llc | 2023-09-30 | 0.0 | |
Jpmorgan Chase & Co | 2023-12-31 | 0.0 |
Lixte Biotechnology Historical Income Statement
Lixte Biotechnology Holdings Income Statement is one of the three primary financial statements used for reporting Lixte's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Lixte Biotechnology revenue and expense. Lixte Biotechnology Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Lixte Biotechnology's Research Development is comparatively stable compared to the past year. Total Other Income Expense Net is likely to gain to 3,372 in 2024, despite the fact that Interest Expense is likely to grow to (15.4 K). View More FundamentalsLixte Stock Against Markets
Picking the right benchmark for Lixte Biotechnology stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Lixte Biotechnology stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Lixte Biotechnology is critical whether you are bullish or bearish towards Lixte Biotechnology Holdings at a given time. Please also check how Lixte Biotechnology's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Lixte Biotechnology without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Alpha Finder Now
Alpha FinderUse alpha and beta coefficients to find investment opportunities after accounting for the risk |
All Next | Launch Module |
Lixte Biotechnology Corporate Directors
Lixte Biotechnology corporate directors refer to members of a Lixte Biotechnology board of directors. The board of directors generally takes responsibility for the Lixte Biotechnology's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Lixte Biotechnology's board members must vote for the resolution. The Lixte Biotechnology board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.Stephen Forman | Director | Profile | |
Kathleen Mullinix | Independent Director | Profile | |
Philip Palmedo | Independent Director | Profile | |
Winson Ho | Director | Profile |
How to buy Lixte Stock?
Before investing in Lixte Biotechnology, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Lixte Biotechnology. To buy Lixte Biotechnology stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Lixte Biotechnology. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Lixte Biotechnology stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Lixte Biotechnology Holdings stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Lixte Biotechnology Holdings stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Lixte Biotechnology Holdings, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Lixte Stock please use our How to Invest in Lixte Biotechnology guide.
Already Invested in Lixte Biotechnology Holdings?
The danger of trading Lixte Biotechnology Holdings is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Lixte Biotechnology is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Lixte Biotechnology. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Lixte Biotechnology is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Lixte Biotechnology is a strong investment it is important to analyze Lixte Biotechnology's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Lixte Biotechnology's future performance. For an informed investment choice regarding Lixte Stock, refer to the following important reports: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lixte Biotechnology Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Complementary Tools for Lixte Stock analysis
When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |
Is Lixte Biotechnology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lixte Biotechnology. If investors know Lixte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lixte Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.66) | Return On Assets (0.64) | Return On Equity (1.11) |
The market value of Lixte Biotechnology is measured differently than its book value, which is the value of Lixte that is recorded on the company's balance sheet. Investors also form their own opinion of Lixte Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Lixte Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lixte Biotechnology's market value can be influenced by many factors that don't directly affect Lixte Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lixte Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lixte Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lixte Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.